» Articles » PMID: 37681034

Inhibition of Nonsense-mediated MRNA Decay Reduces the Tumorigenicity of Human Fibrosarcoma Cells

Overview
Journal NAR Cancer
Specialty Oncology
Date 2023 Sep 8
PMID 37681034
Authors
Affiliations
Soon will be listed here.
Abstract

Nonsense-mediated mRNA decay (NMD) is a eukaryotic RNA decay pathway with roles in cellular stress responses, differentiation, and viral defense. It functions in both quality control and post-transcriptional regulation of gene expression. NMD has also emerged as a modulator of cancer progression, although available evidence supports both a tumor suppressor and a pro-tumorigenic role, depending on the model. To further investigate the role of NMD in cancer, we knocked out the NMD factor SMG7 in the HT1080 human fibrosarcoma cell line, resulting in suppression of NMD function. We then compared the oncogenic properties of the parental cell line, the SMG7-knockout, and a rescue cell line in which we re-introduced both isoforms of SMG7. We also tested the effect of a drug inhibiting the NMD factor SMG1 to distinguish NMD-dependent effects from putative NMD-independent functions of SMG7. Using cell-based assays and a mouse xenograft tumor model, we showed that suppression of NMD function severely compromises the oncogenic phenotype. Molecular pathway analysis revealed that NMD suppression strongly reduces matrix metalloprotease 9 (MMP9) expression and that MMP9 re-expression partially rescues the oncogenic phenotype. Since MMP9 promotes cancer cell migration and invasion, metastasis and angiogenesis, its downregulation may contribute to the reduced tumorigenicity of NMD-suppressed cells. Collectively, our results highlight the potential value of NMD inhibition as a therapeutic approach.

Citing Articles

RNA binding proteins (RBPs) on genetic stability and diseases.

Aborode A, Abass O, Nasiru S, Eigbobo M, Nefishatu S, Idowu A Glob Med Genet. 2025; 12(1):100032.

PMID: 39925443 PMC: 11803229. DOI: 10.1016/j.gmg.2024.100032.


PRMT1 Modulates Alternative Splicing to Enhance HPV18 mRNA Stability and Promote the Establishment of Infection.

Williams D, King K, Jackson R, Kuehner F, Arnoldy C, Marroquin J bioRxiv. 2024; .

PMID: 39386465 PMC: 11463397. DOI: 10.1101/2024.09.26.614592.


ZMAT2 condensates regulate the alternative splicing of TRIM28 to reduce cellular ROS accumulation, thereby promoting the proliferation of HCC cells.

Zhu Y, Li J, Li S, Yang Z, Qiao Z, Gu X Cell Commun Signal. 2024; 22(1):407.

PMID: 39164737 PMC: 11337747. DOI: 10.1186/s12964-024-01790-9.


A Novel Four-Gene Signature Based on Nonsense-Mediated RNA Decay for Predicting Prognosis in Hepatocellular Carcinoma: Bioinformatics Analysis and Functional Validation.

Zhao J, Wang C, Zhao L, Zhou H, Wu R, Zhang T J Hepatocell Carcinoma. 2024; 11:747-766.

PMID: 38680213 PMC: 11055534. DOI: 10.2147/JHC.S450711.


In Vitro Cross-Linking MS Reveals SMG1-UPF2-SMG7 Assembly as Molecular Partners within the NMD Surveillance.

Padariya M, Vojtesek B, Hupp T, Kalathiya U Int J Mol Sci. 2024; 25(6).

PMID: 38542156 PMC: 10969982. DOI: 10.3390/ijms25063182.

References
1.
Losson R, Lacroute F . Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc Natl Acad Sci U S A. 1979; 76(10):5134-7. PMC: 413094. DOI: 10.1073/pnas.76.10.5134. View

2.
Nicholson P, Joncourt R, Muhlemann O . Analysis of nonsense-mediated mRNA decay in mammalian cells. Curr Protoc Cell Biol. 2012; Chapter 27:Unit27.4. DOI: 10.1002/0471143030.cb2704s55. View

3.
Li L, Geng Y, Feng R, Zhu Q, Miao B, Cao J . The Human RNA Surveillance Factor UPF1 Modulates Gastric Cancer Progression by Targeting Long Non-Coding RNA MALAT1. Cell Physiol Biochem. 2017; 42(6):2194-2206. DOI: 10.1159/000479994. View

4.
Kadomatsu T, Endo M, Miyata K, Oike Y . Diverse roles of ANGPTL2 in physiology and pathophysiology. Trends Endocrinol Metab. 2014; 25(5):245-54. DOI: 10.1016/j.tem.2014.03.012. View

5.
Aalinkeel R, Nair B, Reynolds J, Sykes D, Mahajan S, Chadha K . Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest. 2011; 40(5):447-64. DOI: 10.3109/08820139.2011.557795. View